ADDENDUM: CANCER CARE OUTCOMES RESEARCH AND SURVEILLANCE
CONSORTIUM (RFA-CA-01-013)
Release Date: October 4, 2000
NOTICE: CA-01-001
National Cancer Institute
This addendum is to inform potential applicants of three changes to RFA-CA-01-
013 entitled “Cancer Care Outcomes Research and Surveillance Consortium”
released August 24, 2000.
First, a change with regard to minimum enrollment for each Primary Data
Collection and Research (PDCR) site applicant is as follows:
1. Under SPECIAL REQUIREMENTS, Terms and Conditions of Award, Part B, Primary
Data Collection and Research (PDCR) site responsibilities, the minimum
number of patients is changed from 1,000 to 700 patients per cancer (lung
and colorectal).
2. Under APPLICATION PROCEDURES, Specific Instructions for PDCR sites,
instruction number 2, the minimum number of patients to be enrolled is
changed from 1,000 to 700 patients per cancer over a two year accrual
period. As before, applicants are not required to participate in studies
of both lung and colorectal cancer.
3. Under REVIEW CONSIDERATIONS, Specific Review Criteria: PDCR Sites, number
2a, the minimum number of cases is changed from 1,000 per cancer type to
700 per cancer type.
Second, given the reduction of the minimum sample size allowed, all PDCR site
applicants are encouraged to target 1,000 patients per cancer type, if
resources permit, in order to achieve the sample size objective of 6,000
patients per cancer within the CanCORS Consortium as a whole.
The third change is a clarification of the definition of the Principal
Investigator under the section entitled RESEARCH OBJECTIVES, Definitions.
Currently, the definition reads:
“Each institution may have more than one CanCORS PI, and a single person may
be the PI for an application that includes both lung and colorectal cancer.”
The revised statement reads:
“Since there must be a single PI for each application, one person will be the
PI for those applications that include both lung and colorectal cancer. On
such applications, the PI may designate a second individual to be a full
participating member of the CanCORS Steering Committee.”
All other provisions of CA-01-013 remain unchanged. The complete RFA can be
found at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-01-013.html
INQUIRIES
Inquiries are encouraged, and the opportunity to clarify issues and answer
questions is welcome. Inquiries may be directed to:
Arnold L. Potosky, Ph.D.
Division of Cancer Control and Population Sciences
National Cancer Institute
6130 Executive Boulevard, Room 4005, MSC 7344
Bethesda, MD 20892-7344
Telephone: (301) 496-5662
FAX: (301) 435-3710
Email: potosky@nih.gov